Optimal timing for percutaneous coronary intervention in patients undergoing transcatheter aortic valve replacement: A network meta-analysis

IF 2.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiovascular Revascularization Medicine Pub Date : 2025-07-01 Epub Date: 2025-03-06 DOI:10.1016/j.carrev.2025.03.007
Pedro E.P. Carvalho , Bruno Ramos Nascimento , Douglas M. Gewehr , Andre Rivera , Mariana Clemente , Marcelo A.P. Braga , Lucas N. Pansani , Lara Almeidinha , Nicole Felix , Thiago M.A. Veiga , Marco Barbanti , Pedro A. Lemos , Marcos Antônio Marino , Maurizio Taramasso , Philippe Garot
{"title":"Optimal timing for percutaneous coronary intervention in patients undergoing transcatheter aortic valve replacement: A network meta-analysis","authors":"Pedro E.P. Carvalho ,&nbsp;Bruno Ramos Nascimento ,&nbsp;Douglas M. Gewehr ,&nbsp;Andre Rivera ,&nbsp;Mariana Clemente ,&nbsp;Marcelo A.P. Braga ,&nbsp;Lucas N. Pansani ,&nbsp;Lara Almeidinha ,&nbsp;Nicole Felix ,&nbsp;Thiago M.A. Veiga ,&nbsp;Marco Barbanti ,&nbsp;Pedro A. Lemos ,&nbsp;Marcos Antônio Marino ,&nbsp;Maurizio Taramasso ,&nbsp;Philippe Garot","doi":"10.1016/j.carrev.2025.03.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The optimal timing for percutaneous coronary intervention (PCI) in patients undergoing transcatheter aortic valve replacement (TAVR) is uncertain.</div></div><div><h3>Objectives</h3><div>To compare different PCI timings in patients with CAD undergoing TAVR.</div></div><div><h3>Methods</h3><div>MEDLINE, Embase, and Cochrane were systematically searched for studies comparing different timings of PCI in patients with aortic stenosis and coronary artery disease (CAD) undergoing TAVR. PCI in a staged procedure to TAVR and PCI concomitantly to TAVR were compared with TAVR alone without PCI. A frequentist random-effects network meta-analysis calculates the odds ratio (OR) with a 95 % confidence interval (CI). Treatments were ranked using P-score analysis.</div></div><div><h3>Results</h3><div>Two randomized controlled trials and 24 observational studies comprising 10,901 patients with aortic stenosis and CAD were included. Compared with PCI and concomitant TAVR, staged PCI was associated with lower rates of stroke (OR 0.54; 95 % CI 0.37-0.78), myocardial infarction (OR 0.54; 95 % CI 0.31-0.91), and all-cause mortality at 30 days (OR 0.62; 95 % CI 0.41-0.95). In addition, a subgroup analysis showed that staged PCI performed after TAVR is associated with the lowest rates of all-cause mortality of all strategies. In P-score analysis, staged PCI presented the highest likelihood of preventing stroke and myocardial infarction.</div></div><div><h3>Conclusion</h3><div>In patients with aortic stenosis and CAD undergoing TAVR, staged PCI is associated with lower rates of stroke, myocardial infarction, and short-term mortality compared with other timings.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"76 ","pages":"Pages 56-63"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1553838925000740","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The optimal timing for percutaneous coronary intervention (PCI) in patients undergoing transcatheter aortic valve replacement (TAVR) is uncertain.

Objectives

To compare different PCI timings in patients with CAD undergoing TAVR.

Methods

MEDLINE, Embase, and Cochrane were systematically searched for studies comparing different timings of PCI in patients with aortic stenosis and coronary artery disease (CAD) undergoing TAVR. PCI in a staged procedure to TAVR and PCI concomitantly to TAVR were compared with TAVR alone without PCI. A frequentist random-effects network meta-analysis calculates the odds ratio (OR) with a 95 % confidence interval (CI). Treatments were ranked using P-score analysis.

Results

Two randomized controlled trials and 24 observational studies comprising 10,901 patients with aortic stenosis and CAD were included. Compared with PCI and concomitant TAVR, staged PCI was associated with lower rates of stroke (OR 0.54; 95 % CI 0.37-0.78), myocardial infarction (OR 0.54; 95 % CI 0.31-0.91), and all-cause mortality at 30 days (OR 0.62; 95 % CI 0.41-0.95). In addition, a subgroup analysis showed that staged PCI performed after TAVR is associated with the lowest rates of all-cause mortality of all strategies. In P-score analysis, staged PCI presented the highest likelihood of preventing stroke and myocardial infarction.

Conclusion

In patients with aortic stenosis and CAD undergoing TAVR, staged PCI is associated with lower rates of stroke, myocardial infarction, and short-term mortality compared with other timings.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
经导管主动脉瓣置换术患者经皮冠状动脉介入治疗的最佳时机:一项网络meta分析。
背景:经导管主动脉瓣置换术(TAVR)患者经皮冠状动脉介入治疗(PCI)的最佳时机尚不确定。目的:比较CAD患者行TAVR的不同PCI时机。方法:系统检索MEDLINE、Embase和Cochrane,比较主动脉瓣狭窄和冠心病(CAD)患者行TAVR的不同PCI时机的研究。将TAVR分阶段PCI和TAVR合并PCI与TAVR单独不PCI进行比较。频率随机效应网络元分析以95%的置信区间(CI)计算优势比(OR)。采用P-score分析对治疗进行排序。结果:纳入了2项随机对照试验和24项观察性研究,包括10,901例主动脉瓣狭窄和CAD患者。与PCI和合并TAVR相比,分期PCI与较低的卒中发生率相关(OR 0.54;95% CI 0.37-0.78),心肌梗死(OR 0.54;95% CI 0.31-0.91),以及30天的全因死亡率(OR 0.62;95% ci 0.41-0.95)。此外,亚组分析显示,TAVR后进行分阶段PCI与所有策略中全因死亡率最低相关。在P-score分析中,分期PCI预防脑卒中和心肌梗死的可能性最高。结论:在主动脉瓣狭窄和冠心病患者行TAVR时,与其他时间相比,分阶段PCI与较低的卒中、心肌梗死和短期死亡率相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardiovascular Revascularization Medicine
Cardiovascular Revascularization Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.30
自引率
5.90%
发文量
687
审稿时长
36 days
期刊介绍: Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.
期刊最新文献
Conduction disturbance recovery and permanent pacing requirement in bicuspid aortic valves post-TAVR. Obesity as a determinant of radiation burden in the cardiac catheterization laboratory. Drug-coated balloon (SeQuent please neo) versus drug-eluting stent treatment for acute ST-elevation myocardial infarction: Design and rationale of the STEMI DCB trial. Off-label use of microaxial left ventricular assist devices is associated with higher mortality despite use in younger patients with fewer comorbidities. Clinical outcomes of a drug-coated balloon-only strategy for de novo ACC/AHA type B2/C coronary lesions in large vessels: A propensity-matched comparison with drug-eluting stents.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1